Biosimilar
Amgen’s Wezlana Emerges as Competitor to J&J’s Stelara, Shaping Medicare Negotiations
Johnson & Johnson may find a silver lining in the recent FDA approval of Amgen’s biosimilar for Stelara. This approval ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
Samsung wants to describe its Humira biosimilar as “interchangeable.”
While several biosimilars of AbbVie’s top-selling drug, Humira, are already available in the US market, only one, Boehringer Ingelheim’s Cyltezo, ...
Is Biogen giving up its biosims business to Samsung Bioepis?
During the first-quarter earnings call, CEO Chris Viehbacher discussed his plan to revitalize Biogen and emphasized the need to find ...
Teva Expands Alvotech Collaboration with 2 New Biosimilar, $40M Investment & Enhanced Oversight
Source – Teva Pharmaceuticals Following the second FDA rejection of Teva’s Alvotech-partnered biosimilar for Humira, the two companies are expanding ...
Sandoz’s Biosimilar Natalizumab Receives Positive CHMP Opinion for Multiple Sclerosis Treatment
Source – Novartis On July 24, 2023 Sandoz announced a significant milestone. The Committee for Medicinal Products for Human Use ...
Sandoz Plans Biosimilar Technical Development Centre in Slovenia for Future Pipeline Expansion
Source – Novartis July 20, 2023, Sandoz, a renowned global leader in generic and biosimilar medicines, has disclosed a substantial ...
VPAS negotiations are prohibited by the UK High Court from taking place
The British Generic Manufacturers Association (BGMA) has been denied a seat at the negotiation table for the new Voluntary Scheme ...
Humira biosimilar to be made available by RxPreferred via Mark Cuban’s online pharmacy
Pharmacy benefits manager (PBM) RxPreferred has unveiled its plan to provide the Humira biosimilar Yusimry through Mark Cuban Cost Plus ...
To speed up patient access to Biosimilar medications, Sandoz announces the Act4 Biosimilars Action Plan
Source – Novartis On June 15, a global plan to improve patient access to biologic medicines was launched, according to ...
Another Stelara patent settlement was reached by J&J, this time with Alvotech and Teva
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar ...
